Q-Med AB and Oceana Therapeutics achieve key milestone with the submission of a Premarketing Application for FDA approval of Solesta®

Q-Med  AB and Oceana Therapeutics, based in USA, today announced the filing of a
Premarket  Approval (PMA) application with the U.S. Food and Drug Administration
(FDA)  for Solesta(®). Solesta is  a new alternative for  the treatment of fecal
incontinence which affects about 2 percent of the population.

The PMA application contains a substantial amount of clinical data to show the
safety and effectiveness of Solesta(®). The pivotal multi-center, randomized,
Sham (placebo) controlled study represents the main body of clinical evidence in
the PMA submission.  The study met all primary endpoints. These endpoints were
pre-specified in a study protocol approved by the FDA. Treatment effect was
associated with an improvement in quality of life.

Solesta has been under development as a minimally invasive treatment for
patients suffering from fecal incontinence who have failed conservative therapy.
Solesta is an injectable gel administered in an outpatient setting without the
need for anesthesia. Through a transaction finalized in June, 2009, Oceana
Therapeutics obtained the exclusive world wide marketing rights to Solesta from
 Q-Med AB.

Q-Med's President & CEO, Bengt Ågerup, "After many years of dedication we have
succeeded in developing a new treatment to help patients with a socially
debilitating condition and we are very pleased to partner with Oceana in
achieving this important step towards bringing Solesta into the U.S. market.
Solesta, which utilizes our NASHA(TM) technology, is a potentially significant
product and we share in Oceana's enthusiasm regarding the product's growth
prospects."

Cindy Wong, Q-Med's Chief Medical Officer, said "Solesta treatment has been
shown to be safe and effective in patients with fecal incontinence. Improvement
in quality of life was also shown in the studies. There is clearly a need for a
new treatment option and this is reinforced by the interests shown by the
investigators and the patients who participated in the studies. Their commitment
has been essential in the clinical development of Solesta."

John T. Spitznagel, Oceana's Chairman & CEO, said "This represents a major
milestone in the growth of our company.  It is a testimony to the dedication,
experience and excellence of the Oceana team and reflects the strength of our
close working relationship with Q-Med."

Fecal incontinence is estimated to affect about two percent of the population
and seven percent of the population over age 65 years. Current treatment options
are mainly medical treatments or surgery.



For more information from Oceana Therapeutics please visit:  www.oceanathera.com
<http://www.oceanathera.com/>



Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 70 974 9025

Cindy Wong, Chief Medical Officer
Tel: +46 733 871450

Per Langö, Senior Director Corporate Development and Strategy
Tel: +46 733 871521



Q-Med  AB is a medical device  company that develops, manufactures, markets, and
sells  high quality medical implants for  esthetic and medical use. The majority
of  the products are based on  the company's patented technology, NASHA(TM), for
the  production of stabilized non-animal  hyaluronic acid. The product portfolio
today  contains: Restylane® for filling lines and folds, contouring and creating
volume  in the  face, Macrolane(TM)  for body  contouring, Durolane(TM)  for the
treatment  of  osteoarthritis  of  the  hip  and  knee  joints,  Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in  children, and Solesta(TM) for the treatment of fecal incontinence. Sales are
made  through  the  company's  own  subsidiaries  or  distributors  in  over 70
countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's
head  office and production facility  in Uppsala, Sweden. Q-Med  AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


    Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
                          identity number 556258-6882.
      Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com
      <mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.



[HUG#1402370]